Business Context and Reporting Period
Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) filed this Form 8-K on January 24, 2012. The filing reports the entry into a material definitive agreement regarding a new debt offering.
Key Financial Metrics
- Debt Issuance: $250.0 million aggregate principal amount of 8.125% Senior Notes due 2020.
- Interest Rate: 8.125%.
- Maturity: 2020.
- Structure: Senior unsecured obligations of the Issuer (Prestige Brands, Inc.), guaranteed by the Company and certain domestic subsidiaries.
- Expected Closing: On or about January 31, 2012.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, margins, or existing liquidity metrics.
Material Changes and Use of Proceeds
The Company intends to use the net proceeds from the Notes offering, combined with additional senior secured bank debt, for the following purposes:
- Financing the previously announced acquisition of certain North American over-the-counter healthcare brands owned by GlaxoSmithKline plc and its affiliates.
- Repaying existing senior secured credit facilities.
- Paying fees and expenses incurred in connection with these transactions.
- General corporate purposes.
Guidance, Risks, and Unusual Items
- Lock-up Period: The Issuer has agreed not to offer or sell any debt securities issued or guaranteed by the Issuer for 90 days following the purchase agreement date without prior written consent from the initial purchasers.
- Regulatory Status: The Notes are being issued in a private offering exempt from registration under the Securities Act of 1933 (Rule 144A and Regulation S). They are not registered and may not be offered in the U.S. absent registration or an exemption.
- Indemnification: The Issuer has agreed to indemnify initial purchasers against certain liabilities, including those under the Securities Act.
Investor Verification Checklist
- Verify the final closing date of the $250 million Notes offering (expected January 31, 2012).
- Confirm the terms and status of the "additional senior secured bank debt" mentioned as part of the financing plan.
- Review the definitive purchase agreement for specific covenants and representations not detailed in this summary.
- Monitor the progress of the acquisition of GlaxoSmithKline's North American OTC healthcare brands.
- Check subsequent filings for the repayment status of existing senior secured credit facilities.